share_log

Rapid Dose Announces Proposed Equity Private Placement Financing and Proposed Shares for Debt Settlement

Rapid Dose Announces Proposed Equity Private Placement Financing and Proposed Shares for Debt Settlement

Rapid Dose宣佈擬議的股權定向增發融資以及建議的股票債務償還。
newsfile ·  12/11 05:15

Burlington, Ontario--(Newsfile Corp. - December 10, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") today announced that it plans to complete an equity private placement financing (the "Financing") for up to $6,000,000 of gross proceeds, consisting of up to 24,000,000 units (the "Units") at a price of $0.25 per Unit. Each Unit will consist of one (1) Common Share and one (1) Common Share Purchase Warrant (a "Warrant"). Each Warrant will be exercisable for one (1) Common Share for a period of two (2) years from the date of issue, at a price of $0.33 per Common Share.

安大略省伯靈頓--(資訊文件CORP - 2024年12月10日) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT"或"公司")今天宣佈,計劃進行股權定向增發融資("融資"),最多籌集600萬美元的毛收入,包括最多2400萬個單位("單位"),每單位價格爲0.25美元。每個單位將包括一(1)普通股和一(1)普通股購買Warrant("Warrant")。每個Warrant將在發行之日起兩(2)年的期限內可行權,價格爲每普通股0.33美元。

The Company intends to use the proceeds from the Financing for debt retirement, research and development, capital expansion and working capital purposes. The Financing may close in one or more tranches. The securities issued on the Financing will be subject to a four month hold from the applicable date of closing.

公司打算將融資所得用於償還債務、研究與開發、資本擴張和營運資金目的。融資可能會分期完成。融資發行的證券將在適用的成交日期後需要持有四個月。

The Company will be engaging Meadowbank Asset Management Inc. (the "Agent") in respect of the Financing. The Agent will be entitled to a cash commission equal to 1% of the aggregate gross proceeds raised pursuant to the Financing from investors introduced to the Company by the Agent. The Company shall also issue such number of agent warrants (each, an "Agent Warrant") as is equal to 6% of the number of Units issued to investors in the Financing that were introduced to the Company by the Agent. Each Agent Warrant will be exercisable to acquire one (1) Common Share at a price of $0.33 per Common Share for a term of two (2) years from the date of issuance of such Agent Warrant.

公司將與Meadowbank資產管理公司("代理人")合作進行融資。代理人將有權獲得相當於融資中由代理人介紹的投資者所募集的總毛收入的1%的現金佣金。公司還將發行等於融資中由代理人介紹的投資者所發行的單位數量的6%的代理Warrant(每個稱爲"代理Warrant")。每個代理Warrant將在發行之日起兩(2)年的期限內,價格爲每普通股0.33美元,可以購買一(1)普通股。

RDT also announces that it intends to enter into debt settlement agreements with certain of its creditors (the "Creditors") to issue up to an aggregate of 1,600,000 common shares (the "Settlement Shares") to such Creditors in exchange for the cancellation of outstanding accounts payable (the "Shares for Debt Transaction") in the aggregate amount of up to $400,000 (the "Debt") owing to such Creditors. The Settlement Shares will be issued at a price equal to the greater of $0.25 per share and the share price on the close of business five (5) days after the date of this press release, in accordance with the policies of the Canadian Securities Exchange (the "CSE").

RDt還宣佈計劃與部分債權人("債權人")簽訂債務和解協議,向這些債權人發行最多160萬個普通股("和解股份"),以換取取消未償帳戶應付("以股份償債交易"),總金額最高達40萬美元("債務")。和解股份的發行價格將等於每股0.25美元和本新聞稿發佈日期後五(5)個工作日的收盤股價中的較高者,符合加拿大證券交易所("CSE")的政策。

The Company is completing the Shares for Debt Transaction to improve its financial position by reducing its existing liabilities. All Settlement Shares issued to Canadian residents will be subject to a four-month hold period from the date of issuance. The Shares for Debt Transaction remains subject to CSE acceptance. No new control person of the Company will be created pursuant to the Shares for Debt Transaction.

該公司正在完成股份以債務交易,以通過減少現有負債來改善其財務狀況。所有發放給加拿大居民的結算股份將從發行日期起受四個月的持有期限制。股份以債務交易仍需獲得CSE的接受。根據股份以債務交易,不會創造公司的新控制人。

About Rapid Dose Therapeutics Corp.
Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The Company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient. For more information about the Company, visit .

關於Rapid Dose Therapeutics CORP.
Rapid Dose Therapeutics是一家加拿大生物技術公司,通過創新革命性地改變藥物遞送。公司的旗艦產品QuickStrip是一種薄型口服可溶膜,可以注入無限種活性成分,包括營養藥物、藥品和疫苗,這些成分能夠快速進入血液,從而迅速發揮活性成分的作用。有關公司的更多信息,請訪問。

Contacts:
Mark Upsdell, CEO
416-477-1052

聯繫方式:
馬克·厄普斯戴爾,首席執行官
416-477-1052

RDT Investor Contact:
Investor Relations
investorrelations@rapid-dose.com
416-477-1052

RDt投資者聯繫:
投資者關係
investorrelations@rapid-dose.com
416-477-1052

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:

關於前瞻性聲明的警告說明:

Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "intend", "may", "should", "anticipate", "expect", "potential", "believe", "intend", "will", "could", "are planned to", "are expected to" or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of equipment and products using the QuickStrip product delivery method, the generation of recurring revenues, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, statements pertaining to the use of funds from the Financing and the anticipated closing of the Financing and Shares for Debt Transaction, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

本新聞稿中的某些信息可能包含適用證券法下的前瞻性信息。任何在本新聞稿中包含的不是歷史事實的陳述可能被視爲前瞻性聲明。前瞻性聲明通常通過以下術語識別:"打算"、"可能"、"應該"、"預期"、"期望"、"潛在"、"相信"、"將"、"可以"、"計劃"、"預計"或這些術語的否定形式及類似表達。包含前瞻性信息的聲明,包括但不限於針對使用QuickStrip產品交付方法的設備和產品交付、產生重複收入的計劃、RDt管理層對未來事件或結果的估計、預測、預期或信念,基於目前可用的信息被認爲是合理的。前瞻性聲明必然涉及已知和未知的風險,包括但不限於,涉及從融資中使用資金和預計結束融資以及債務換股交易的聲明,伴隨的一般經濟狀況風險;不利的行業事件;市場營銷成本;市場喪失;WLm協議的終止;涉及大麻的未來立法和監管發展;無法從內部和外部來源獲得足夠資本,以及/或無法以優惠條件獲得足夠資本;加拿大的一般大麻行業,所得稅和監管事務;實施其業務戰略的能力;競爭;貨幣和利率波動及其他風險。讀者應注意上述列表並非詳盡無遺。無法保證,儘管在準備時被RDt管理層認爲合理,但前瞻性信息的陳述仍可能準確無誤,因爲無法保證基於這些計劃、意圖或期望的情況將會發生。實際結果和未來事件可能與這些前瞻性聲明中預期的有重大差異。讀者不應過度依賴前瞻性聲明。本新聞稿中包含的前瞻性聲明明確由本警告聲明予以限定。此新聞稿中包含的前瞻性聲明是在本新聞稿日期發佈的,且公司明確否認任何更新或修改包含任何前瞻性信息的聲明或其基礎或假設的義務,無論是由於新信息、未來事件還是其他原因,除非法律要求。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the United States. The securities described in this news release have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

本新聞稿不構成出售要約或買入要約的邀請,並且在任何法律禁止此類要約、邀請或銷售的司法管轄區內不會進行任何證券的銷售。本新聞稿不構成在美國出售或邀請出售本文所述證券的要約。本文所述證券未在美國1933年證券法("美國證券法")或任何州證券法下注冊,也不會註冊,除非根據美國證券法和適用的州證券法登記,或者有可用的免於此類註冊的豁免,否則不得在美國或向美國人士提供或出售。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論